

---

## Nordic Society of Gynaecological Oncology – Clinical Trial Unit

### Program

# NSGO-CTU Biannual Investigator Meeting 28-29 November 2019

Radisson Blu Scandinavia Hotel, Copenhagen  
Amager Blvd. 70, 2300 København

**This meeting is partly sponsored by**





## Thursday 28 November 2019

18.00 – 19.00 **Buffet**

19.00 – 21.20 **NSGO-CTU Symposium**

**Chair:** *Johanna Mäenpää, Tampere, Finland*

### PARP inhibitors in combination

19.00 – 19.20 **Rationale and clinical evidence of PARP inhibitors in combination with other novel agents**, *Mansoor Raza Mirza, NSGO-CTU*

19.20 – 20.00 **PAOLA study results and beyond**, *Eric Pujade-Lauraine, GINECO, France*

20.00 – 20.20 **Translation research in PARP inhibitor**, *Line Bjørge, Bergen, Norway*

20.20 – 21.20 **Panel discussion**

*Eric Pujade-Lauraine, GINECO, France*

*Johanna Mäenpää, Tampere, Finland*

*Susanne Malander, Lund, Sweden*

*Line Bjørge, Bergen, Norway*

*Henrik Roed, Copenhagen, Denmark*

*Ingvild Vistad, Kristiansand, Norway*

*Mansoor Raza Mirza, NSGO-CTU*

NSGO-CTU Scientific Symposium is an official part of NSGO-CTU Biannual Investigator meeting program with NSGO-CTU being solely responsible for the content. The Symposium is supported by a sponsorship from a pharmaceutical company.

## Friday 29 November 2019

07.30 – 08.00 **Registration/coffee**

08.00 – 09.40 **NSGO-CTU Symposium**

**Chair:** *Kristina Lindemann, Oslo, Norway*

### Patient's perspective

08:00 – 08:40 **Patient's acceptance of novel treatments**, *Jalid Sehouli, Berlin, Germany*

08:40 – 08:55 **Patient's view**, *Birthe Lemley, KIU, Denmark*

08:55 – 09:10 **"No decision about me – without me" – Shared decision making as a concept**,

*Karina Dahl Steffensen, Vejle, Denmark*

09:10 – 09:25 **The role of patient-reported outcomes in palliation**,

*Kristina Lindemann, Oslo, Norway*

09:25 – 09:45 **Panel Discussion**

*Jalid Sehouli, Berlin, Germany*

*Maria Dimoula, Sahlgrenska, Sweden*

*Karina Dahl Steffensen, Vejle, Denmark*

*Annika Auranen, Tampere, Finland*

*Gitte-Bettina Nyvang, Odense, Denmark*

NSGO-CTU Scientific Symposium is an official part of NSGO-CTU Biannual Investigator meeting program with NSGO-CTU being solely responsible for the content. The Symposium is supported by a sponsorship from a pharmaceutical company.

10.00 – 10.05 **Welcome**

*Mansoor Raza Mirza, NSGO-CTU*

10.05 – 10.15 **Future plans and status report of NSGO-CTU activities**, *Mansoor Raza Mirza, NSGO-CTU*

## **OVARIAN CANCER**

10.15 – 10.45 **Surgical trials** – Scientific rationale, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact.

*Chair: Johanna Mäenpää, Tampere, Finland*

10.15 – 10.25 Overview of Surgical trials:

- **AGO-OVAR OP.4/DESKTOP III**

- **TRUST**

*Johanna Mäenpää, Tampere, Finland*

10.25 – 10.35 **OVHIPEC-2**

*Berit Jul Mosgaard, Copenhagen, Denmark*

10.35 – 10.45 **Panel discussion**

*Ulla Puistola, Oulu, Finland*

*Päivi Lindvall Kannisto, Lund, Sweden*

*Yun Wang, Oslo, Norway*

*Berit Jul Mosgaard, Copenhagen, Denmark*

## **OVARIAN CANCER**

10.45 – 11.45 **First line trials** - Scientific rationale, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome

*Chair: Henrik Roed, Copenhagen, Denmark*

10.45 – 11.00 **Overview of First line trials:**

- **AGO-OVAR 17/BOOST**

- **AGO-OVAR12**

- **AGO-OVAR16**

- **ENGOT-ov39/IMagyn050**

- **ENGOT-ov25/PAOLA-1**

- **PRIMA/ENGOT-OV26/GOG-3012**

*Henrik Roed, Copenhagen, Denmark*

11.00 – 11.10 **ENGOT-ov44/First** - An adaptive Randomized Phase 3 Comparison of Standard Platinum Based Treatment Versus Platinum and TSR-042 followed by Niraparib and TSR-042 maintenance Therapy in Patients with epithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum

*Gitte-Bettina Nyvang, Odense, Denmark*

11.10 – 11.20 **DUO-O** - Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

*Maarit Anttila, Kuopio, Finland*

11.20 – 11.30 **ENGOT-ov45/NCRI/ATHENA** - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

*Susanne Malander, Lund, Sweden*

11.30 – 11.45 **Panel discussion**

*Gitte-Bettina Nyvang, Odense, Denmark*

*Maarit Anttila, Kuopio, Finland*

*Susanne Malander, Lund, Sweden*

*Henna Kärkkäinen, Kuopio, Finland*

*Kristine Madsen, Copenhagen, Denmark*

*Nicoline Raaschou-Jensen, Herlev, Denmark*

*Birute Brasiuniene, Vilnius, Lithuania*

## **OVARIAN CANCER**

11.45 – 12.40 **Relapsed disease** - Scientific rationale, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome

*Chair: Line Bjørge, Bergen, Norway*

11.45 – 11.55 **Overview of trials where platinum is an option:**

- **INOVATYON**

- **ENGOT-ov16/NOVA**

- **ENGOT-ov24-NSGO/AVANOVA**

- **ENGOT-ov38/OREO**

*Line Bjørge, Bergen, Norway*

11.55 – 12.05 **ENGOT-OV42-NSGO/AVATAR** – A three-arm randomized study to evaluate the efficacy of niraparib-bevacizumab-dostarlimab triplet combination against niraparib-bevacizumab doublet combination and against standard of care therapy in Women with relapsed ovarian cancer where platinum combination therapy is an option.

*Mansoor Mirza, NSGO-CTU*



## 12.05 – 12.20 Panel discussion

*Synnöve Staff, Tampere, Finland*  
*Hanna Dahlstrand, Uppsala, Sweden*  
*Morten Jørgensen, Rigshospitalet, Denmark*  
*Elisabeth Berge Nilsen, Stavanger, Norway*  
*Mansoor Raza Mirza, NSGO-CTU*

**LUNCH** 12.20-13.20

## OVARIAN CANCER

13.20 – 13.40 **Relapsed disease** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome  
*Chair: Annika Auranen, Tampere, Finland*

13.20 – 13.30 **ENGOT-ov34/2.29** – Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab standard in recurrent ovarian cancer – a randomized Phase III trial  
*Sakari Hietanen, Turku, Finland*

13.30 – 13.40 **ENGOT-ov30/NSGO-UMBRELLA** – A multicenter, phase 2, open-label non-randomized study to obtain preliminary evidence of efficacy of several novel combinations in relapsed ovarian cancer. This information regards Cohorte A, MEDI9447 and Durvalumab  
*Liv Cecilie Vestrheim Thomsen, Bergen, Norway*

13.40 – 13.50 **Panel discussion**  
*Sakari Hietanen, Turku, Finland*  
*Mansoor Raza Mirza, NSGO-CTU*  
*Liv Cecilie Vestrheim Thomsen, Bergen, Norway*  
*Ulla Puistola, Oulu, Finland*  
*Elisabeth Berge Nilsen, Stavanger, Norway*  
*Gerli Kuusk, Tallinn, Estonia*

## ENDOMETRIAL CANCER

13.50 – 14.45 **Endometrial Cancer** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome  
*Chair: Caroline Lundgren, Karolinska, Sweden*

13.50 – 14.00 **ENGOT-EN2-DGCG** – A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer  
*Bente Lund, Aalborg, Denmark*

14.00 – 14.10 **ENGOT-EN1/FANDANGO** – A Randomized Phase II Trial of First-line Combination Chemotherapy with Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer  
*Hanna Dahlstrand, Uppsala, Sweden*

14.10 – 14.20 **ENGOT-EN3-NSGO/PALEO** – A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer  
*Anne Dørum, Oslo, Norway*

14.20 – 14.30 **ENGOT-EN6-NSGO/RUBY** – A Phase 3 Randomized Open-Label Study of TSR-042, an anti-PD-1 Monoclonal Antibody, Versus Investigator's Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer  
*Mansoor Raza Mirza, NSGO-CTU*

14.30 – 14.45 **Panel discussion**  
*Bente Lund, Aalborg, Denmark*  
*Hanna Dahlstrand, Uppsala, Sweden*  
*Anne Dørum, Oslo, Norway*  
*Mansoor Raza Mirza, NSGO-CTU*  
*Marjut Rintala, Turku, Finland*  
*Kathrine Woie, Bergen, Norway*  
*Karin Grisan, Tartu, Estonia*

**COFFEE** 14.45 – 15.05

## **CERVICAL and VULVAR CANCER**

15.05 – 16.30 **Cervical Cancer** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome  
*Chair: Ane Gerda Zahl Eriksson, Oslo, Norway*

15.05 – 15.15 Update of minimal invasive surgery – **RACC trial**  
*Sahar Salehi, Stockholm, Sweden*

15.15 – 15.25 **ENGOT-cx7-NSGO/MaRuC**  
**ENGOT-cx11** – A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer  
*Mansoor Raza Mirza, NSGO-CTU*

15.25 – 15.35 **ENGOT-cx10/GEICO 68-C/BEAT cc** – A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix  
*Kristina Lindemann, Oslo, Norway*

- 15.35 – 15.45 **ENGOT-cx13/AGO/FERMATA** – An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer  
*Farrukh Chaudhary, Herlev, Denmark*
- 15.45 – 15.55 **ENGOT-cx6** – Tisotumab Vedotin in Previously treated recurrent or metastatic cervical cancer.  
**ENGOT-cx8** – Randomized, open label, phase 1b/2 first line trial with Tisotumab Vedotin.  
**ENGOT-cx12** – A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer.  
*Lars Fokdal, Århus, Denmark*
- 15.55 – 16.05 **GROINSS V III**  
*Kristina Lindemann, Oslo, Norway*
- 16.05 – 16.15 **PEACE** – Palliation in gynae-oncology: Evaluation and Assessment of satisfaction with care  
*Kristina Lindemann, Oslo, Norway*
- 16.15 – 16.30 **Panel discussion**  
*Sahar Salehi, Stockholm, Sweden*  
*Mansoor Raza Mirza, NSGO-CTU*  
*Kristina Lindemann, Oslo, Norway*  
*Farrukh Chaudhary, Herlev, Denmark*  
*Lars Fokdal, Århus, Denmark*  
*Johanna Mäenpää, Tampere, Finland*  
*Birute Brasiuniene, Vilnius, Lithuania*
- 16.30 – 16.40 **End of meeting**  
*Mansoor Raza Mirza, NSGO-CTU*

NSGO-CTU will reimburse travel expenses maximum 200 Euros each for one investigator and one research nurse from an NSGO site.